A Phase 1/2 interventional study of bomedemstat and tretinoin in Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA). Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-11.
Sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Leukemia, Myeloid, Acute by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Leukemia, Myeloid, Acute · Merck & Co., Inc.
Among the 12 studies in Leukemia, Myeloid, Acute by Merck & Co., Inc, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 1/2, and was the 9th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →None of the 12 studies in Leukemia, Myeloid, Acute by Merck & Co., Inc is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 2 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 37 across the 12 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA), one of the names counted as Merck & Co., Inc. Under that name alone:
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Leukemia, Myeloid, Acute by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open label study of the dose and duration of an orally administered lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat, in patients with high-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Some participants may also receive all-trans retinoic acid (ATRA; also known as tretinoin and Vesanoid®) in combination with bomedemstat. This study investigates the following:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
High-risk Acute Myeloid Leukemia (AML)
High-risk Myelodysplastic Syndromes (MDS)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive bomedemstat 0.75 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
Drug: bomedemstat
Participants receive bomedemstat 1.5 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
Drug: bomedemstat
Participants receive bomedemstat 3 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
Drug: bomedemstat
Participants receive bomedemstat 6 mg/kg/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
Drug: bomedemstat
Participants receive bomedemstat 3 mg/kg/day orally plus tretinoin 45 mg/m\^2/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
Drug: bomedemstat · Drug: tretinoin
Participants receive bomedemstat 6 mg/kg/day orally plus tretinoin 45 mg/m\^2/day orally in 14-day cycles consisting of 7 days of treatment and 7 days of rest. Participants will receive up to 4 cycles (14-day cycles) for up to a total of up 56 days (28 days on treatment).
Drug: bomedemstat · Drug: tretinoin
Participants receive bomedemstat 6 mg/kg/day orally plus tretinoin 45 mg/m\^2/day orally in 21-day cycles consisting of 14 days of treatment and 7 days of rest. Participants will receive up to 2 cycles (21-day cycles) for up to a total of up 42 days (28 days on treatment).
Drug: bomedemstat · Drug: tretinoin
Participants receive bomedemstat 6 mg/kg/day orally for 21 days plus tretinoin 45 mg/m\^2/day orally in 28-day cycles consisting of 21 days of treatment and 7 days of rest. Participants will receive at least 1 cycle (28-day cycles) and will receive subsequent cycles at the discretion of the investigator.
Drug: bomedemstat · Drug: tretinoin
oral administration
Also known as: MK-3543, IMG-7289
oral administration
Also known as: ATRA®, Vesanoid®, all-trans retinoic acid,
Number of Participants Who Experienced an Adverse Event (AE)
An AE was defined as any undesirable physical, psychological, or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not related to the study drug. This included any untoward signs or symptoms experienced by the participant from the time of first dose until completion of the study. The number of participants who experienced an AE is presented.
Time frame: Up to approximately 24 months
Number of Participants Who Experienced a Serious Adverse Event (SAE)
An SAE was defined as any adverse event, whether or not related to the study drug, that resulted in any of the following outcomes: * Death * Life-threatening experience * Required or prolonged inpatient hospitalization * Persistent or significant disability/incapacity * Congenital anomaly * Important medical events that, based upon appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes listed above. The number of participants who experienced an SAE is presented.
Time frame: Up to approximately 24 months
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
An AE was defined as any undesirable physical, psychological, or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not related to the study drug. This included any untoward signs or symptoms experienced by the participant from the time of first dose until completion of the study. The number of participants who discontinued study treatment due to an AE is presented.
Time frame: Up to approximately 18 months
Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)
DLTs were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. A DLT was defined as any of the following events that occurs during the DLT evaluation period and is considered by the Investigator possibly, probably, or definitely related to bomedemstat: * A clinically significant bleeding event * Any Grade 4 or 5 non-haematologic adverse event * Any Grade 3 non-haematologic adverse event with failure to recover to Grade 1 within 7 days of drug cessation, with the following exceptions: ≥ Grade 3 nausea, vomiting or diarrhoea that responds to standard medical care and ≥ Grade 3 aesthenia lasting less than 14 days * Any Grade 3 electrolyte abnormality unrelated to the underlying malignancy and persisting greater than 24 hours. Per protocol, DLTs were measured during the first 28-day treatment period. The number of participants who experienced a DLT is presented.
Time frame: Up to approximately 28 Days
Number of Participants Experiencing Any Grade 3 to 5 Adverse Events (AE) as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03
AEs were graded for severity on a scale of 1 to 5 using CTCAE criteria. Grade 1=mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2=moderate, minimal, local, or noninvasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3=severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care. Grade 4=life-threatening consequences with urgent intervention indicated. Grade 5 =death related to AE. The number of participants who experienced any Grade 3 to 5 AE is reported.
Time frame: Up to approximately 24 months
Number of Participants Who Experienced a Medical Event of Interest (MEOI)
Medical Events of Interest (MEOI) were adverse events that did not meet any criteria for a serious adverse event but were of particular interest in the context of the study. MEOIs included bleeding due to low platelets; electrocardiogram (ECG) QT corrected interval prolonged 481-500 milliseconds; and infection where, at a minimum, oral antibiotic, antifungal, or antiviral intervention is indicated. The number of participants with MEOIs is presented.
Time frame: Up to approximately 24 months
Maximum Concentration (Cmax) of Bomedemstat Alone or Administered With Tretinoin
Cmax was defined as the maximum concentration of bomedemstat observed after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the CMax of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). Unbound plasma concentrations of bomedemstat were estimated by assuming that protein binding was 60.57%. For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the Cmax was determined for participants in Cohort 1. The LOQ of the assay was 1 ng/mL. The Cmax of bomedemstat in unbound plasma is presented.
Time frame: Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Time to Maximum Concentration (Tmax) of Bomedemstat Alone or Administered With Tretinoin
Tmax was the time required to reach the maximum concentration of bomedemstat observed after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the TMax of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the Tmax was determined for participants in Cohort 1. The Tmax of bomedemstat in plasma is presented.
Time frame: Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Area Under the Concentration Time Curve From Time 0 to 24 Hours (AUC0-24hr) Postdose of Bomedemstat Alone or Administered With Tretinoin
AUC0-24hr was defined as the total exposure of bomedemstat over 24 hours after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the AUC 0-24hr of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). Unbound plasma concentrations of bomedemstat were estimated by assuming that protein binding was 60.57%. For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the AUC 0-24hr was determined for participants in Cohort 1. The AUC 0-24hr of bomedemstat in unbound plasma is presented.
Time frame: Cycle 1 Day 1: predose and 1, 2, 3, and 24 hours postdose; Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Elimination Half Life (t1/2) of Bomedemstat Alone or Administered With Tretinoin
t1/2 was the time required to divide the bomedemstat concentration by two after reaching pseudo-equilibrium after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the t1/2 of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the t1/2 was determined for participants in Cohort 1. The t1/2 of bomedemstat in plasma is presented.
Time frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Apparent Total Body Clearance (CL/F) of Bomedemstat Alone or Administered With Tretinoin
CL/F was the volume of plasma from which bomedemstat was eliminated per unit of time after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the CL/F of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the CL/F was determined for participants in Cohort 1. The CL/F of bomedemstat in plasma is presented.
Time frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Volume of Distribution (Vz/F) of Bomedemstat Alone or Administered With Tretinoin
Vz/F was the volume of distribution of bomedemstat during the terminal phase after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the Vz/F of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the Vz/F was determined for participants in Cohort 1. The Vz/F of bomedemstat in plasma is presented.
Time frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Terminal Elimination Rate Constant (Kel) of Bomedemstat Alone or Administered With Tretinoin
kel was the rate at which bomedemstat was removed from the body by excretion or metabolism after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the kel of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). kel was obtained from the slope of the line, fitted by linear least squares regression, through the terminal points of the log (base e) concentration-time profiles. For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the kel was determined for participants in Cohort 1. The kel of bomedemstat in plasma is presented.
Time frame: Cycle 1 Day 7: predose and 0.5, 1, 2, 3, 4, 8, and 24 hours postdose
Event-free Survival (EFS) For High-risk Acute Myeloid Leukemia (AML) Participants
EFS was defined as the time from the first dose of study treatment to the date of a documented EFS event of resistance, relapse, progression, or death due to any cause as assessed by the investigator. Participants without documented events were censored at the date of the last disease assessment. The EFS, calculated using the Kaplan-Meier method, is presented.
Time frame: Up to approximately 24 months
Event-free Survival (EFS) For High-risk Myelodysplastic Syndromes (MDS) Participants
EFS was defined as the time from the first dose of study treatment to the date of a documented EFS event of resistance, relapse, progression, or death due to any cause as assessed by the investigator. Participants without documented events were censored at the date of the last disease assessment. The EFS, calculated using the Kaplan-Meier method, is presented.
Time frame: Up to approximately 24 months
Overall Survival (OS) For High-risk Acute Myeloid Leukemia (AML) Participants
OS was defined as the time from the first dose of study treatment until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS, calculated using the Kaplan-Meier method, is presented.
Time frame: Up to approximately 24 months
Overall Survival (OS) For High-risk Myelodysplastic Syndromes (MDS) Participants
OS was defined as the time from the first dose of study treatment until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS, calculated using the Kaplan-Meier method, is presented.
Time frame: Up to approximately 24 months
Objective Response Rate (ORR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the Investigator
ORR was the percentage of participants with a response of complete remission (CR), CR with incomplete recovery (Cri), morphologic leukaemia-free state (MLFS), partial remission (PR), cytogenetic CR (CRc), molecular CR (CRm), or stable disease (SD): * CR: \<5% bone marrow (BM) blasts or blasts with Auer rods; no extramedullary disease (EMD); absolute neutrophil count ≥1000/μL; platelets ≥100,000/μL; independent of transfusion * Cri: CR with residual neutropenia (\<1,000/μL) or thrombocytopenia (\<100,000/μL); no EMD; does not require transfusion independence (TI) * MLFS: \<5% blasts in BM with marrow spicules; no EMD; does not require TI * PR: ≥ 50% decrease in BM blasts to a range of 5%-25%; Neutrophils ≥ 1,000/μL; Platelets ≥ 100,000/μL; independent of transfusion. ≤ 5% blasts is PR if Auer rods present * CRc: CR+reversion to a normal karyotype if initially abnormal * CRm: CR+no evidence of residual disease by molecular testing * SD: No evidence of CR, PR, progression, new dysplastic changes
Time frame: Up to approximately 24 months
Best Overall Response (BOR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the Investigator
BOR was the percentage of participants with a best overall response of CR, Cri, MLFS, PR, CRc, CRm, or SD: * CR: \<5% bone marrow (BM) blasts or blasts with Auer rods; no extramedullary disease (EMD); absolute neutrophil count ≥1000/μL; platelets ≥100,000/μL; independent of transfusion * Cri: CR with residual neutropenia (\<1,000/μL) or thrombocytopenia (\<100,000/μL); no EMD; does not require transfusion independence (TI) * MLFS: \<5% blasts in BM with marrow spicules; no EMD; does not require TI * PR: ≥ 50% decrease in BM blasts to a range of 5%-25%; Neutrophils ≥ 1,000/μL; Platelets ≥ 100,000/μL; independent of transfusion. ≤ 5% blasts is PR if Auer rods present * CRc: CR+reversion to a normal karyotype if initially abnormal * CRm: CR+no evidence of residual disease by molecular testing * SD: No evidence of CR, PR, progression, new dysplastic changes
Time frame: Up to approximately 24 months
Objective Response Rate (ORR) For High-risk Myelodysplastic Syndromes (MDS) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006) and Assessed by the Investigator
ORR was the percentage of participants with a response of complete remission (CR), partial remission (PR), marrow CR (CRm), cytogenetic response (CyR), or stable disease (SD) lasting for ≥4 weeks: * CR: ≤5% myeloblasts in the bone marrow (BM) with normal maturation of all cell lines; persistent dysplasia will be noted; Hgb ≥11 g/dL, Platelets ≥100 X 10\^9/L, Neutrophils ≥1.0 X 10\^9/L, and 0% Blasts in the peripheral blood * PR: All CR criteria if abnormal before treatment except: BM blasts decreased by ≥50% over pretreatment but still \>5%. Cellularity and morphology not relevant * CRm: ≤ 5% myeloblasts in BM and decrease by ≥50% over pretreatment. Hematological improvement responses in the peripheral blood will be noted in addition to bone marrow CR. * CyR: Complete=Disappearance of the chromosomal abnormality without appearance of new ones. Partial= ≥50% reduction of the chromosomal abnormality * SD: Failure to achieve at least PR, but no evidence of progression for \>8 weeks
Time frame: Up to approximately 24 months
Best Overall Response (BOR) Assessed by the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006): High-risk Myelodysplastic Syndromes (MDS) Participants
BOR was the percentage of participants with a best overall response of CR, PR, CRm, CyR, or SD lasting for ≥4 weeks: * CR: ≤5% myeloblasts in the bone marrow (BM) with normal maturation of all cell lines; persistent dysplasia will be noted; Hgb ≥11 g/dL, Platelets ≥100 X 10\^9/L, Neutrophils ≥1.0 X 10\^9/L, and 0% Blasts in the peripheral blood * PR: All CR criteria if abnormal before treatment except: BM blasts decreased by ≥50% over pretreatment but still \>5%. Cellularity and morphology not relevant * CRm: ≤ 5% myeloblasts in BM and decrease by ≥50% over pretreatment. Hematological improvement responses in the peripheral blood will be noted in addition to bone marrow CR. * CyR: Complete=Disappearance of the chromosomal abnormality without appearance of new ones. Partial= ≥50% reduction of the chromosomal abnormality * SD: Failure to achieve at least PR, but no evidence of progression for \>8 weeks
Time frame: Up to approximately 24 months
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Erythrocyte Count in Whole Blood After Administration of Bomedemstat
Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in erythrocyte count was measured. Baseline was the erythrocyte count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in erythrocyte count is presented.
Time frame: Baseline (prior to first dose of study drug) and up to 28 days
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Neutrophil Count in Whole Blood After Administration of Bomedemstat
Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in neutrophil count was measured. Baseline was the neutrophil count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in neutrophil count is presented.
Time frame: Baseline (prior to first dose of study drug) and up to 28 days
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Platelet Count in Whole Blood After Administration of Bomedemstat
Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in platelet count was measured. Baseline was the platelet count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in platelet count is presented.
Time frame: Baseline (prior to first dose of study drug) and up to 28 days
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Reticulocyte Count in Whole Blood After Administration of Bomedemstat
Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in reticulocyte count was measured. Baseline was the reticulocyte count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in reticulocyte count is presented.
Time frame: Baseline (prior to first dose of study drug) and up to 28 days
Maximum Percent Change From Baseline Up to 28 Days of Treatment in The Number of Blasts in Whole Blood After Administration of Bomedemstat
Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in the number of blasts was measured. Baseline was the number of blasts at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in the number of blasts is presented.
Time frame: Baseline (prior to first dose of study drug) and up to 28 days
Maximum Percent Change From Baseline Up to 28 Days of Treatment in Hemoglobin Level in Whole Blood After Administration of Bomedemstat
Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in the hemoglobin level was measured. Baseline was the hemoglobin level at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in hemoglobin level is presented.
Time frame: Baseline (prior to first dose of study drug) and up to 28 days
| Milestone | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Started | 3 | 6 | 4 | 6 | 5 | 9 | 4 | 8 |
| Treated | 3 | 6 | 4 | 6 | 5 | 9 | 4 | 8 |
| Completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Not completed | 3 | 6 | 4 | 6 | 5 | 8 | 4 | 6 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 2 | 3 | 2 | 1 | 0 | 4 |
| Withdrew: Physician decision | 1 | 3 | 0 | 0 | 1 | 4 | 2 | 1 |
| Withdrew: Protocol defined disease progression | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Participant withdrawal of consent | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 1 |
An AE was defined as any undesirable physical, psychological, or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not related to the study drug. This included any untoward signs or symptoms experienced by the participant from the time of first dose until completion of the study. The number of participants who experienced an AE is presented.
| Participants | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 3 | 6 | 4 | 6 | 5 | 9 | 4 | 8 |
An SAE was defined as any adverse event, whether or not related to the study drug, that resulted in any of the following outcomes: * Death * Life-threatening experience * Required or prolonged inpatient hospitalization * Persistent or significant disability/incapacity * Congenital anomaly * Important medical events that, based upon appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes listed above. The number of participants who experienced an SAE is presented.
| Participants | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced a Serious Adverse Event (SAE) | 3 | 6 | 4 | 5 | 5 | 9 | 4 | 8 |
An AE was defined as any undesirable physical, psychological, or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not related to the study drug. This included any untoward signs or symptoms experienced by the participant from the time of first dose until completion of the study. The number of participants who discontinued study treatment due to an AE is presented.
| Participants | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) | 2 | 2 | 3 | 3 | 0 | 1 | 0 | 0 |
DLTs were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. A DLT was defined as any of the following events that occurs during the DLT evaluation period and is considered by the Investigator possibly, probably, or definitely related to bomedemstat: * A clinically significant bleeding event * Any Grade 4 or 5 non-haematologic adverse event * Any Grade 3 non-haematologic adverse event with failure to recover to Grade 1 within 7 days of drug cessation, with the following exceptions: ≥ Grade 3 nausea, vomiting or diarrhoea that responds to standard medical care and ≥ Grade 3 aesthenia lasting less than 14 days * Any Grade 3 electrolyte abnormality unrelated to the underlying malignancy and persisting greater than 24 hours. Per protocol, DLTs were measured during the first 28-day treatment period. The number of participants who experienced a DLT is presented.
| Participants | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AEs were graded for severity on a scale of 1 to 5 using CTCAE criteria. Grade 1=mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2=moderate, minimal, local, or noninvasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3=severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care. Grade 4=life-threatening consequences with urgent intervention indicated. Grade 5 =death related to AE. The number of participants who experienced any Grade 3 to 5 AE is reported.
| Participants | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Any Grade 3 to 5 Adverse Events (AE) as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 | 3 | 6 | 4 | 5 | 5 | 9 | 4 | 8 |
Medical Events of Interest (MEOI) were adverse events that did not meet any criteria for a serious adverse event but were of particular interest in the context of the study. MEOIs included bleeding due to low platelets; electrocardiogram (ECG) QT corrected interval prolonged 481-500 milliseconds; and infection where, at a minimum, oral antibiotic, antifungal, or antiviral intervention is indicated. The number of participants with MEOIs is presented.
| Participants | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced a Medical Event of Interest (MEOI) | 1 | 1 | 1 | 2 | 0 | 3 | 0 | 0 |
Cmax was defined as the maximum concentration of bomedemstat observed after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the CMax of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). Unbound plasma concentrations of bomedemstat were estimated by assuming that protein binding was 60.57%. For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the Cmax was determined for participants in Cohort 1. The LOQ of the assay was 1 ng/mL. The Cmax of bomedemstat in unbound plasma is presented.
| nanograms/milliliter | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 10.7 ± 12.6 | 19.6 ± 19.0 | 65.7 ± 22.9 | 145 ± 85.5 | 66.8 ± 27.3 | 205 ± 112 |
| Cycle 1 Day 7 | 9.67 ± 12.0 | 18.1 ± 10.4 | 72.2 ± 26.0 | 202 ± 111 | 119 ± 72.1 | 291 ± 211 |
Tmax was the time required to reach the maximum concentration of bomedemstat observed after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the TMax of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the Tmax was determined for participants in Cohort 1. The Tmax of bomedemstat in plasma is presented.
| hours | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 1.00 (0.93 to 3.00) | 2.00 (0.93 to 3.05) | 1.00 (0.92 to 2.08) | 2.06 (1.00 to 3.03) | 1.00 (0.92 to 1.17) | 1.02 (0.97 to 2.50) |
| Cycle 1 Day 7 | 0.77 (0.53 to 1.00) | 1.50 (0.45 to 3.08) | 1.73 (0.47 to 3.05) | 1.53 (0.53 to 3.08) | 0.50 (0.50 to 0.83) | 0.88 (0.00 to 3.93) |
AUC0-24hr was defined as the total exposure of bomedemstat over 24 hours after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the AUC 0-24hr of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). Unbound plasma concentrations of bomedemstat were estimated by assuming that protein binding was 60.57%. For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the AUC 0-24hr was determined for participants in Cohort 1. The AUC 0-24hr of bomedemstat in unbound plasma is presented.
| hours●nanograms/milliliter | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 26.4 ± 39.2 | 78.6 ± 36.8 | 323 ± 142 | 1361 ± 789 | 287 ± 113 | 1138 ± 621 |
| Cycle 1 Day 7 | 68.8 ± 90.4 | 129 ± 78.0 | 550 ± 247 | 1361 ± 747 | 383 ± 116 | 1702 ± 1326 |
t1/2 was the time required to divide the bomedemstat concentration by two after reaching pseudo-equilibrium after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the t1/2 of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the t1/2 was determined for participants in Cohort 1. The t1/2 of bomedemstat in plasma is presented.
| hours | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|
| Elimination Half Life (t1/2) of Bomedemstat Alone or Administered With Tretinoin | 130 ± NA | 103 ± 23.3 | 103 ± 8.21 | 110 ± 49.6 | — | 59.8 ± 29.4 |
CL/F was the volume of plasma from which bomedemstat was eliminated per unit of time after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the CL/F of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the CL/F was determined for participants in Cohort 1. The CL/F of bomedemstat in plasma is presented.
| liters/hour | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|
| Apparent Total Body Clearance (CL/F) of Bomedemstat Alone or Administered With Tretinoin | 5.754 ± 7.711 | 1.351 ± 1.246 | 492 ± 322 | 401 ± 211 | 472 ± 88.3 | 287 ± 131 |
Vz/F was the volume of distribution of bomedemstat during the terminal phase after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the Vz/F of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the Vz/F was determined for participants in Cohort 1. The Vz/F of bomedemstat in plasma is presented.
| liters | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|
| Volume of Distribution (Vz/F) of Bomedemstat Alone or Administered With Tretinoin | 56354 ± NA | 224527 ± 122456 | 99822 ± 74167 | 63895 ± 24473 | — | 22539 ± 6061 |
kel was the rate at which bomedemstat was removed from the body by excretion or metabolism after administration of bomedemstat alone or administered with tretinoin. Plasma samples were collected at multiple time points to estimate the kel of bomedemstat using non-compartmental methods of analysis following oral dosing of participants in Cycle 1 (Cycle 1 = 7 days of treatment and 7 days of rest for a total of 14 days). kel was obtained from the slope of the line, fitted by linear least squares regression, through the terminal points of the log (base e) concentration-time profiles. For the pharmacokinetic analysis, plasma concentrations below the assay limit of quantitation (LOQ) that occurred from predose to the first concentration ≥LOQ were treated as 0 and those that occured thereafter were treated as missing. The LOQ of the assay was 1 ng/mL. Per protocol, the kel was determined for participants in Cohort 1. The kel of bomedemstat in plasma is presented.
| 1/hour | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|
| Terminal Elimination Rate Constant (Kel) of Bomedemstat Alone or Administered With Tretinoin | 0.0053 ± NA | 0.0071 ± 0.0020 | 0.0068 ± 0.0005 | 0.0074 ± 0.0031 | — | 0.0135 ± 0.0059 |
EFS was defined as the time from the first dose of study treatment to the date of a documented EFS event of resistance, relapse, progression, or death due to any cause as assessed by the investigator. Participants without documented events were censored at the date of the last disease assessment. The EFS, calculated using the Kaplan-Meier method, is presented.
| Months | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Event-free Survival (EFS) For High-risk Acute Myeloid Leukemia (AML) Participants | 0.87 (0.80 to 0.93) | 0.97 (0.93 to NA) | 0.93 (0.90 to 18.81) | 2.46 (0.97 to NA) | 0.93 (0.93 to 3.96) | NA (0.50 to NA) | 1.43 (1.40 to 1.46) | 0.93 (0.47 to 5.59) |
EFS was defined as the time from the first dose of study treatment to the date of a documented EFS event of resistance, relapse, progression, or death due to any cause as assessed by the investigator. Participants without documented events were censored at the date of the last disease assessment. The EFS, calculated using the Kaplan-Meier method, is presented.
| Months | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Event-free Survival (EFS) For High-risk Myelodysplastic Syndromes (MDS) Participants | NA (NA to NA) | — | — | — | 0.75 (0.57 to 0.93) | NA (NA to NA) | — | NA (NA to NA) |
OS was defined as the time from the first dose of study treatment until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS, calculated using the Kaplan-Meier method, is presented.
| Months | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) For High-risk Acute Myeloid Leukemia (AML) Participants | NA (0.80 to NA) | NA (NA to NA) | 18.81 (1.17 to 18.81) | 3.86 (1.07 to NA) | NA (1.86 to NA) | NA (1.36 to NA) | NA (NA to NA) | NA (0.47 to NA) |
OS was defined as the time from the first dose of study treatment until death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS, calculated using the Kaplan-Meier method, is presented.
| Months | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) For High-risk Myelodysplastic Syndromes (MDS) Participants | NA (NA to NA) | — | — | — | NA (0.57 to NA) | NA (NA to NA) | — | NA (NA to NA) |
ORR was the percentage of participants with a response of complete remission (CR), CR with incomplete recovery (Cri), morphologic leukaemia-free state (MLFS), partial remission (PR), cytogenetic CR (CRc), molecular CR (CRm), or stable disease (SD): * CR: \<5% bone marrow (BM) blasts or blasts with Auer rods; no extramedullary disease (EMD); absolute neutrophil count ≥1000/μL; platelets ≥100,000/μL; independent of transfusion * Cri: CR with residual neutropenia (\<1,000/μL) or thrombocytopenia (\<100,000/μL); no EMD; does not require transfusion independence (TI) * MLFS: \<5% blasts in BM with marrow spicules; no EMD; does not require TI * PR: ≥ 50% decrease in BM blasts to a range of 5%-25%; Neutrophils ≥ 1,000/μL; Platelets ≥ 100,000/μL; independent of transfusion. ≤ 5% blasts is PR if Auer rods present * CRc: CR+reversion to a normal karyotype if initially abnormal * CRm: CR+no evidence of residual disease by molecular testing * SD: No evidence of CR, PR, progression, new dysplastic changes
| Percentage of participants | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) For High-risk Acute Myeloid Leukemia (AML) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2003) and Assessed by the Investigator | 50.0 (1.3 to 98.7) | 16.7 (0.4 to 64.1) | 25.0 (0.6 to 80.6) | 50.0 (11.8 to 88.2) | 33.3 (0.8 to 90.6) | 28.6 (3.7 to 71.0) | 0.0 (NA to NA) | 28.6 (3.7 to 71.0) |
BOR was the percentage of participants with a best overall response of CR, Cri, MLFS, PR, CRc, CRm, or SD: * CR: \<5% bone marrow (BM) blasts or blasts with Auer rods; no extramedullary disease (EMD); absolute neutrophil count ≥1000/μL; platelets ≥100,000/μL; independent of transfusion * Cri: CR with residual neutropenia (\<1,000/μL) or thrombocytopenia (\<100,000/μL); no EMD; does not require transfusion independence (TI) * MLFS: \<5% blasts in BM with marrow spicules; no EMD; does not require TI * PR: ≥ 50% decrease in BM blasts to a range of 5%-25%; Neutrophils ≥ 1,000/μL; Platelets ≥ 100,000/μL; independent of transfusion. ≤ 5% blasts is PR if Auer rods present * CRc: CR+reversion to a normal karyotype if initially abnormal * CRm: CR+no evidence of residual disease by molecular testing * SD: No evidence of CR, PR, progression, new dysplastic changes
| Percentage of participants | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Complete remission (CR) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| CR with incomplete recovery (CRi) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Morphologic leukaemia-free state (MLFS) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Partial remission (PR) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14.3 | 0.0 | 0.0 |
| Cytogenetic CR (CRc) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Molecular CR (CRm) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Stable disease (SD) | 50.0 | 16.7 | 25.0 | 50.0 | 33.3 | 14.3 | 0.0 | 28.6 |
ORR was the percentage of participants with a response of complete remission (CR), partial remission (PR), marrow CR (CRm), cytogenetic response (CyR), or stable disease (SD) lasting for ≥4 weeks: * CR: ≤5% myeloblasts in the bone marrow (BM) with normal maturation of all cell lines; persistent dysplasia will be noted; Hgb ≥11 g/dL, Platelets ≥100 X 10\^9/L, Neutrophils ≥1.0 X 10\^9/L, and 0% Blasts in the peripheral blood * PR: All CR criteria if abnormal before treatment except: BM blasts decreased by ≥50% over pretreatment but still \>5%. Cellularity and morphology not relevant * CRm: ≤ 5% myeloblasts in BM and decrease by ≥50% over pretreatment. Hematological improvement responses in the peripheral blood will be noted in addition to bone marrow CR. * CyR: Complete=Disappearance of the chromosomal abnormality without appearance of new ones. Partial= ≥50% reduction of the chromosomal abnormality * SD: Failure to achieve at least PR, but no evidence of progression for \>8 weeks
| Percentage of participants | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) For High-risk Myelodysplastic Syndromes (MDS) Participants Determined Using the Revised/Modified International Working Group (IWG) Response Criteria (Cheson et al., 2006) and Assessed by the Investigator | 100.0 (2.5 to 100.0) | — | — | — | 0.0 (NA to NA) | 0.0 (NA to NA) | — | 0.0 (NA to NA) |
BOR was the percentage of participants with a best overall response of CR, PR, CRm, CyR, or SD lasting for ≥4 weeks: * CR: ≤5% myeloblasts in the bone marrow (BM) with normal maturation of all cell lines; persistent dysplasia will be noted; Hgb ≥11 g/dL, Platelets ≥100 X 10\^9/L, Neutrophils ≥1.0 X 10\^9/L, and 0% Blasts in the peripheral blood * PR: All CR criteria if abnormal before treatment except: BM blasts decreased by ≥50% over pretreatment but still \>5%. Cellularity and morphology not relevant * CRm: ≤ 5% myeloblasts in BM and decrease by ≥50% over pretreatment. Hematological improvement responses in the peripheral blood will be noted in addition to bone marrow CR. * CyR: Complete=Disappearance of the chromosomal abnormality without appearance of new ones. Partial= ≥50% reduction of the chromosomal abnormality * SD: Failure to achieve at least PR, but no evidence of progression for \>8 weeks
| Percentage of participants | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Complete remission (CR) | 0.0 | — | — | — | 0.0 | 0.0 | — | 0.0 |
| Partial remission (PR) | 0.0 | — | — | — | 0.0 | 0.0 | — | 0.0 |
| Marrow CR (CRm) | 0.0 | — | — | — | 0.0 | 0.0 | — | 0.0 |
| Cytogenetic response (CyR) | 0.0 | — | — | — | 0.0 | 0.0 | — | 0.0 |
| Stable disease (SD) | 100.0 | — | — | — | 0.0 | 0.0 | — | 0.0 |
Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in erythrocyte count was measured. Baseline was the erythrocyte count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in erythrocyte count is presented.
| Percent change | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day |
|---|---|---|---|---|
| Maximum Percent Change From Baseline Up to 28 Days of Treatment in Erythrocyte Count in Whole Blood After Administration of Bomedemstat | 4.4 ± 6.66 | 16.7 ± 19.43 | 17.0 ± 5.83 | 21.4 ± 14.97 |
Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in neutrophil count was measured. Baseline was the neutrophil count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in neutrophil count is presented.
| Percent change | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day |
|---|---|---|---|---|
| Maximum Percent Change From Baseline Up to 28 Days of Treatment in Neutrophil Count in Whole Blood After Administration of Bomedemstat | 198.4 ± 206.33 | 223.3 ± 259.61 | 198.8 ± 273.54 | 3218.0 ± 7780.65 |
Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in platelet count was measured. Baseline was the platelet count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in platelet count is presented.
| Percent change | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day |
|---|---|---|---|---|
| Maximum Percent Change From Baseline Up to 28 Days of Treatment in Platelet Count in Whole Blood After Administration of Bomedemstat | 21.9 ± 18.15 | 30.4 ± 73.39 | 313.6 ± 529.94 | 8.1 ± 20.79 |
Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in reticulocyte count was measured. Baseline was the reticulocyte count at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in reticulocyte count is presented.
| Percent change | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day |
|---|---|---|---|---|
| Maximum Percent Change From Baseline Up to 28 Days of Treatment in Reticulocyte Count in Whole Blood After Administration of Bomedemstat | 47.3 ± 102.51 | 57.1 ± 52.48 | 133.5 ± 158.03 | 26.6 ± 51.64 |
Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in the number of blasts was measured. Baseline was the number of blasts at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in the number of blasts is presented.
| Percent change | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day |
|---|---|---|---|---|
| Maximum Percent Change From Baseline Up to 28 Days of Treatment in The Number of Blasts in Whole Blood After Administration of Bomedemstat | 368.0 ± 399.54 | 2478.3 ± 3278.96 | 9.7 ± 25.23 | 2841.4 ± 6046.61 |
Whole blood samples were collected at time intervals during the first 4 cycles (Cycle length = 7 days of treatment and 7 days of rest for a total of 14 days), which corresponds to 28 days on treatment. The percent change from baseline in the hemoglobin level was measured. Baseline was the hemoglobin level at screening or the last available observation prior to the first dose of study drug. An analysis of treatment effect between the doses was determined using a Kruskal-Wallis test. This analysis was done to support the evaluation of plasma concentrations (Cmax and Cmin) and exposure (AUC) on haematopoiesis. Per protocol, the analysis was pre-specified to be done on participants that received bomedemstat alone. The maximum percent change from baseline in hemoglobin level is presented.
| Percent change | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day |
|---|---|---|---|---|
| Maximum Percent Change From Baseline Up to 28 Days of Treatment in Hemoglobin Level in Whole Blood After Administration of Bomedemstat | 1262.1 ± 429.99 | 476.5 ± 710.28 | 12.6 ± 3.76 | 134.4 ± 296.96 |
Collected over Up to approximately 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1a: Bomedemstat 0.75 mg/kg/Day | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| Cohort 1b: Bomedemstat 1.5 mg/kg/Day | 0/6 (0%) | 6/6 (100%) | 6/6 (100%) |
| Cohort 1c: Bomedemstat 3 mg/kg/Day | 2/4 (50%) | 4/4 (100%) | 4/4 (100%) |
| Cohort 1d: Bomedemstat 6 mg/kg/Day | 3/6 (50%) | 5/6 (83.3%) | 6/6 (100%) |
| Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | 2/5 (40%) | 5/5 (100%) | 5/5 (100%) |
| Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | 2/9 (22.2%) | 9/9 (100%) | 9/9 (100%) |
| Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | 1/4 (25%) | 4/4 (100%) | 4/4 (100%) |
| Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | 4/8 (50%) | 8/8 (100%) | 8/8 (100%) |
| Event | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 3/6 | 2/4 | 4/6 | 1/5 | 4/9 | 0/4 | 4/8 |
| SepsisInfections and infestations | 0/3 | 0/6 | 2/4 | 0/6 | 1/5 | 0/9 | 0/4 | 0/8 |
| CellulitisInfections and infestations | 0/3 | 2/6 | 0/4 | 0/6 | 2/5 | 1/9 | 1/4 | 0/8 |
| Ear painEar and labyrinth disorders | 1/3 | 0/6 | 0/4 | 0/6 | 0/5 | 0/9 | 0/4 | 0/8 |
| MalaiseGeneral disorders | 1/3 | 0/6 | 0/4 | 0/6 | 0/5 | 0/9 | 0/4 | 0/8 |
| PyrexiaGeneral disorders | 1/3 | 1/6 | 0/4 | 0/6 | 0/5 | 0/9 | 0/4 | 1/8 |
| EpiglottitisInfections and infestations | 1/3 | 0/6 | 0/4 | 0/6 | 0/5 | 0/9 | 0/4 | 0/8 |
| InfectionInfections and infestations | 1/3 | 0/6 | 0/4 | 0/6 | 0/5 | 0/9 | 0/4 | 0/8 |
| Periorbital infectionInfections and infestations | 1/3 | 0/6 | 0/4 | 0/6 | 0/5 | 0/9 | 0/4 | 0/8 |
| Subdural haemorrhageInjury, poisoning and procedural complications | 1/3 | 0/6 | 0/4 | 0/6 | 0/5 | 0/9 | 0/4 | 0/8 |
| Event | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day |
|---|---|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 3/3 | 4/6 | 1/4 | 3/6 | 2/5 | 3/9 | 1/4 | 3/8 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 4/6 | 4/4 | 2/6 | 1/5 | 6/9 | 4/4 | 7/8 |
| NauseaGastrointestinal disorders | 3/3 | 3/6 | 2/4 | 5/6 | 2/5 | 7/9 | 2/4 | 5/8 |
| HypomagnesaemiaMetabolism and nutrition disorders | 0/3 | 3/6 | 4/4 | 1/6 | 1/5 | 6/9 | 1/4 | 1/8 |
| Decreased appetiteMetabolism and nutrition disorders | 1/3 | 1/6 | 3/4 | 0/6 | 1/5 | 3/9 | 1/4 | 3/8 |
| VomitingGastrointestinal disorders | 0/3 | 2/6 | 2/4 | 4/6 | 2/5 | 4/9 | 1/4 | 5/8 |
| Oedema peripheralGeneral disorders | 1/3 | 4/6 | 2/4 | 0/6 | 1/5 | 4/9 | 0/4 | 5/8 |
| HypokalaemiaMetabolism and nutrition disorders | 1/3 | 3/6 | 2/4 | 3/6 | 2/5 | 6/9 | 2/4 | 3/8 |
| HypophosphataemiaMetabolism and nutrition disorders | 0/3 | 1/6 | 1/4 | 1/6 | 0/5 | 6/9 | 2/4 | 2/8 |
| DizzinessNervous system disorders | 2/3 | 2/6 | 1/4 | 1/6 | 0/5 | 1/9 | 0/4 | 0/8 |
All participants who received ≥1 dose of study treatment
| Age, Continuous(Years) | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 72.3 ± 10.02 | 74.2 ± 9.24 | 74.0 ± 10.95 | 66.8 ± 11.14 | 67.2 ± 14.65 | 71.8 ± 9.00 | 68.5 ± 2.08 | 70.5 ± 11.65 | 70.6 ± 9.98 |
| Sex: Female, Male(Participants) | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 1 | 1 | 4 | 6 | 2 | 3 | 19 |
| Male | 2 | 5 | 3 | 5 | 1 | 3 | 2 | 5 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 2 | 4 | 4 | 6 | 4 | 8 | 3 | 6 | 37 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 7 |
| Race (NIH/OMB)(Participants) | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 2 | 5 | 4 | 5 | 5 | 7 | 4 | 7 | 39 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 5 |
| Disease Diagnosis(Participants) | Cohort 1a: Bomedemstat 0.75 mg/kg/Day | Cohort 1b: Bomedemstat 1.5 mg/kg/Day | Cohort 1c: Bomedemstat 3 mg/kg/Day | Cohort 1d: Bomedemstat 6 mg/kg/Day | Cohort 1x3: Bomedemstat 3 mg/kg/Day Orally Plus Tretinoin 45 mg/m^2/Day | Cohort 1x6: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 3x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Cohort 4x: Bomedemstat 6 mg/kg/Day Plus Tretinoin 45 mg/m^2/Day | Total |
|---|---|---|---|---|---|---|---|---|---|
| AML | 2 | 6 | 4 | 6 | 3 | 7 | 4 | 7 | 39 |
| MDS | 1 | 0 | 0 | 0 | 2 | 2 | 0 | 1 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2016 to primary completion in Oct 2018, 24 months.
Results were first posted in Jul 2023, 4 years 8 months after primary completion.
Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 24 months is below that.
Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bomedemstat
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) →